AGN194204|220619-73-8|(IRX4204; NRX194204; VTP 194204)-陌孚医药/Medlife

您当前的位置：

AGN194204 (Synonyms: IRX4204; NRX194204; VTP 194204)

目录号: PL10816 纯度: ≥99.0%

CAS No. :220619-73-8

商品编号	规格	价格	会员价
PL10816-1mg	1mg	¥5666.00	请登录
PL10816-5mg	5mg	询价	询价
PL10816-10mg	10mg	询价	询价
PL10816-50mg	50mg	询价	询价

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	AGN194204
中文别名	(2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7 ,8-tetrahydro-2-naphthalenyl)cyclopropyl]-2,4-pentadienoic acid
英文名称	AGN194204
英文别名	(2e,4e)-3-methyl-5-[(1s,2s)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7 ,8-tetrahydro-2-naphthalenyl)cyclopropyl]-2,4-pentadienoic Acid;AGN-194204;AGN194204
Cas No.	220619-73-8
分子式	C₂₄H₃₂O₂
分子量	352.52
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情

AGN194204 (IRX4204) 是一种具有口服活性的，选择性 RXR 激动剂，对 RXRα，RXRβ 和 RXRγ 的 K_d 值分别为 0.4 nM，3.6 nM 和 3.8 nM，EC₅₀ 分别为 0.2 nM，0.8 nM 和 0.08 nM。AGN194204 对 RAR 无活性，并具有抗炎和抗癌作用。

生物活性

AGN194204 (IRX4204) is an orally active and selective RXR agonist with K d values 0.4 nM, 3.6 nM and 3.8 nM and EC 50 s of 0.2 nM, 0.8 nM and 0.08 nM for RXRα, RXRβ and RXRγ, respectively. AGN194204 is inactive against RAR. AGN194204 has anti-inflammatory and anticarcinogenic actions.

性状

Solid

体外研究(In Vitro)

AGN194204 (NRX194204; 0-100 nM; 24 hours; E, RAW cells) treatment blocks the ability of lipopolysaccharide and tumor necrosis factor-α to induce the release of nitric oxide and interleukin 6 and the degradation of IKBα in RAW264.7 macrophage-like cells.
AGN194204 (NRX194204; 1 μM; 72 hours; SK-BR-3 human breast cancer cells) treatment induces apoptosis in breast cancer cells. has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

AGN194204 (NRX194204; 30-60 mg/kg; oral administration; daily; for 15 weeks; female A/J mice) treatment significantly reduces the number and size of tumors on the surface of the lungs and reduces the total tumor volume per slide by 64% to 81% compared with the control group. has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder -20°C 3 years；4°C 2 years

ClinicalTrial

参考文献

[1]. Liby K, et al. A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland. Clin Cancer Res. 2007 Oct 15;13(20):6237-43.
[2]. Vuligonda V, et al. Enantioselective syntheses of potent retinoid X receptor ligands: differential biological activities of individual antipodes. J Med Chem. 2001 Jul 5;44(14):2298-303.

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation